Pazopanib - GlaxoSmithKline/Novartis

Drug Profile

Pazopanib - GlaxoSmithKline/Novartis

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Duke University Medical Center; GlaxoSmithKline; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; SCRI Development Innovations; University of Minnesota; University of Oxford; University of Washington
  • Class Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Sarcoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastrointestinal stromal tumours; Glioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Malignant melanoma
  • No development reported Colorectal cancer; Hepatocellular carcinoma; Prostate cancer
  • Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

Most Recent Events

  • 30 Nov 2017 Phase-II clinical trials in Renal cell carcinoma (Late-stage disease, Second-line therapy or greater) in Hungary, Austria, Germany, Spain, Czech Republic (PO) (NCT03200717) (EudraCT2017-000708-10)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy) in European Union (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy) in India (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top